EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors

Indrani Choudhuri, Jocelyn G Olvera, Avik Biswas iD, Allan Haldane, Ronald M Levy iD, Dmitry Lyumkis iD

Viruses · 08.05.2026 · 18 (5) · 540

DOI: 10.3390/v18050540 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 08.05.2026. Verfasst von Indrani Choudhuri und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Salk Institute for Biological Studies, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: Drug Resistance, Viral, HIV Integrase Inhibitors, HIV-1, HIV Integrase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Gilead Sciences (United States), california hiv research program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HIV-1 integrase (IN) strand transfer inhibitors (INSTIs) are central to modern antiretroviral therapy (ART) because of their high potency and durable effect on viral suppression. However, drug resistance mutations (DRMs) within HIV-1 IN emerge, which can compromise long-term treatment efficacy. Many distinct DRMs that arise under INSTI therapy have been extensively tabulated in public repositories and literature. However, the timelines over which they emerge, accumulate, and consolidate in patients have not been systematically integrated across clinical and experimental studies. In this review, we synthesize current evidence on the temporal evolution of DRMs within HIV-1 IN by examining mutational kinetic data from viruses derived from people living with HIV/AIDS (PLWH) and from in vitro selection experiments. We compare experimental timelines to recent computational predictions derived from Potts-based fitness landscapes coupled with kinetic Monte Carlo simulations and identify reproducible kinetic classes that distinguish fast-, intermediate-, and slow-emerging DRMs. Rapidly emerging DRMs such as E92Q and N155H typically appear early under drug pressure and often represent low-barrier adaptive responses, whereas the most clinically consequential mutations, such as Q148H/K/R, G140A/S, and E138K, arise only after extended therapy and generally require compensatory mutational backgrounds to persist. Although absolute emergence times vary substantially between in vivo and in vitro systems, consistent temporal trends across datasets support the existence of underlying epistatic constraints that shape drug resistance evolution. Understanding DRM timelines is clinically relevant because it provides a framework for interpreting resistance detected at virological failure, informs optimal timing of resistance testing, and may enable earlier identification of high-risk evolutionary trajectories before durable resistance is established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, ViralHIV Integrase InhibitorsHIV-1HIV IntegraseEvolution, MolecularHIV InfectionsHumansMutation

Stichwörter der Autor:innen

antiretroviral therapydrug resistanceepistasisintegraseresistance evolutionstrand transfer inhibitorsviral fitness

Substanzen

HIV Integrase InhibitorsHIV Integrasep31 integrase protein, Human immunodeficiency virus 1

Autor:innen und Institutionen

  • The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
  • Molecular Biology Section, Division of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.
  • Department of Physics, University of California San Diego, La Jolla, CA 92093, USA.
  • Department of Physics, Temple University, Philadelphia, PA 19122, USA.
  • Department of Chemistry, Temple University, Philadelphia, PA 19122, USA.

ORCID-Profile: Avik Biswas, Ronald M Levy, Dmitry Lyumkis

Förderung

  • NIAID NIH HHS
  • Gilead Sciences (United States)
  • california hiv research program
  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Science Foundation
  • Schmidt Family Foundation
  • National Institutes of Health

Zitieren

APA

Choudhuri, I., Olvera, J. G., Biswas, A., Haldane, A., Levy, R. M., & Lyumkis, D. (2026). Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors. Viruses, 18(5), 540. https://doi.org/10.3390/v18050540

Vancouver

Choudhuri I, Olvera JG, Biswas A, Haldane A, Levy RM, Lyumkis D. Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors. Viruses. 2026;18(5):540. doi:10.3390/v18050540

BibTeX
@article{Choudhuri2026,
  author = {Choudhuri, Indrani and Olvera, Jocelyn G and Biswas, Avik and Haldane, Allan and Levy, Ronald M and Lyumkis, Dmitry},
  title = {Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {540},
  doi = {10.3390/v18050540}
}
Kostenlos starten →